Charles River to Acquire Vigene Biosciences, Expanding Gene Therapy Capabilities; Maintain $170 FVE

Charles River announced it will acquire Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO) for $292.5 million in cash. The transaction is expected to close in the third quarter of 2021, and the deal includes additional payments of up to $57.5 million contingent on future performance. Management anticipates funding the acquisition through its existing credit facility, which has a borrowing capacity of up to $3 billion.